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Abstract
Compelling evidence has shown that the effects of antidepressants, increasing extracellular serotonin and
noradrenaline as a primary mechanism of action, involve neuroplastic and neurotrophic mechanisms. Brain-
derived neurotrophic factor (BDNF) has been shown to play a key role in neuroplasticity and synaptic function,
as well as in the pathophysiology of neuropsychiatric disorders and the mechanism of action of antidepressants.
The expression of BDNF is mediated by the transcription of different mRNAs derived by the splicing of one of
the eight 5′ non-coding exons with the 3′ coding exon (in rats). The transcription of each non-coding exon is
driven by unique and different promoters. We generated a gene reporter system based on hippocampal and
cortical neuronal cultures, in which the transcription of luciferase is regulated by BDNF promoters I, II, IV or
by cAMP response element (CRE), to investigate the activation of selected promoters induced by monoaminergic
antidepressants and by serotonin or noradrenaline agonists. We found that incubation with ﬂuoxetine or rebox-
etine failed to induce any activation of BDNF promoters or CRE. On the other hand, the incubation of cultures
with selective agonists of serotonin or noradrenaline receptors induced a speciﬁc and distinct proﬁle of activation
of BDNF promoters I, II, IV and CRE, suggesting that the monoaminergic input, absent in dissociated cultures,
is essential for the modulation of BDNF expression. In summary, we applied a rapidly detectable and highly
sensitive reporter gene assay to characterize the selective activation proﬁle of BDNF and CRE promoters, through
speciﬁc and different pharmacological stimuli.
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Introduction
Dysfunction in monoaminergic pathways has been impli-
cated in the pathophysiology of depression and, consist-
ently, selective serotonin (5-HT) and 5-HT/noradrenaline
(NA) reuptake inhibitors (SSRIs and SNRIs, respectively)
are the most frequently prescribed drugs as ﬁrst line treat-
ment for depression. However, the increase of extracellu-
lar levels of monoamines represents only the ﬁrst step of
the antidepressant effect. Indeed, mood disorders are
associated with alterations in synaptogenesis, dendritic
remodelling and neurogenesis in hippocampal, prefrontal
cortical and limbic regions (McEwen, 2005; Pittenger and
Duman, 2008; Gorman and Docherty, 2010; Sanacora
et al., 2012). On the other hand, chronic antidepressants
evoke adaptive changes in intracellular signalling path-
ways, ultimately inducing plastic modiﬁcations that
could explain the need for long-term treatment to achieve
clinical efﬁcacy (Popoli et al., 2001; Tardito et al., 2006;
Castrén et al., 2007; Racagni and Popoli, 2008; Ryan
et al., 2009; Krishnan and Nestler, 2010).
In line with these observations, converging evidence
has implicated changes in the neurotrophin brain-derived
neurotrophic factor (BDNF)/TrkB signalling pathway
both in the pathophysiology of depression, and in anti-
depressant action. Reduced BDNF expression has been
observed in the hippocampus and prefrontal cortex of
depressed patients (Chen et al., 2001; Dwivedi et al.,
2003; Thompson et al., 2011; Birkenhäger et al., 2012).
Moreover, changes in BDNF mRNA and protein levels
were measured after chronic antidepressants, suggesting
a role of BDNF in the action of the drugs (Dias et al.,
2003; Russo-Neustadt et al., 2004; Dwivedi et al., 2006;
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Khundakar and Zetterström, 2006; Calabrese et al., 2007;
Wang et al., 2008; Alboni et al., 2010; Baj et al., 2012).
The bdnf rat gene is composed of eight untranslated
5′ exons and one 3′ exon encoding the protein (Aid
et al., 2007). Different transcript isoforms are expressed
by splicing each of the non-coding exons to the coding
exon (9). Although the function of the different BDNF
transcripts is not yet completely understood, a differential
role during plasticity-associated changes has been sug-
gested (West et al., 2001; Chiaruttini et al., 2008). The dif-
ferent 5′ exons are transcribed from unique and
alternative promoters, used as a versatile mechanism to
create ﬂexibility in the regulation of gene expression
and subcellular mRNA localization (Aid et al., 2007;
Chiaruttini et al., 2008; Pruunsild et al., 2011). To date,
the promoters of BDNF exons 1, 2 and 4 (respectively,
promoter I, II and IV) have been studied in more detail
(Tabuchi et al., 2002; Takeuchi et al., 2002; Tao et al.,
2002; Pruunsild et al., 2011). BDNF promoter I contains
calcium response elements (CaREs), bound by CRE bind-
ing protein (CREB) and upstream stimulatory factors 1/2
(USF1/USF2), and a binding site for the nuclear factor kB
(NF-kB) (Tabuchi et al., 2002; Kairisalo et al., 2009). BDNF
promoter I and II are negatively regulated by repressor
element-1 (RE-1)-silencing transcription factor (REST) on
their neuron restrictive silencer elements (NRSE)
(Timmusk et al., 1999; Hara et al., 2009). Promoter IV is
strongly activity-responsive and is the most extensively
studied at the molecular level (Shieh et al., 1998;
West et al., 2001). A tight temporal, spatial and stimulus-
speciﬁc regulation of BDNF promoter IV is achieved by a
complex interplay between multiple activity-regulated
transcriptional pathways. Three CaREs are selectively
bound and cooperatively regulated by the transcription
factor calcium-response factor (CaRF), USF1/USF2 and
CREB (Shieh et al., 1998; Tao et al., 1998; Chen et al.,
2003). Moreover, an alternative transcription start site
is regulated by the association of NF-kB (Lipsky et al.,
2001) and the basic helix–loop–helix (bHLH) protein
bHLHB2 (Jiang et al., 2008), with elements localized be-
tween the two transcription start sites. Finally, neuronal
activity-dependent activation of both BDNF promoters
I and IV was found to be dependent on ARNT2/NPAS4
binding to an asymmetric E-box-like element (Pruunsild
et al., 2011).
Although there is a general agreement that chronic
antidepressants increase BDNF transcription in vivo, it is
not known if this effect can be replicated in vitro in pri-
mary neuronal cultures. Therefore, in the present study,
we used an in vitro gene reporter system based on pri-
mary neuronal cultures to characterize the transcriptional
regulation of BDNF promoters I, II and IV, and CRE pro-
moter after in vitro incubation with monoaminergic anti-
depressants (ﬂuoxetine (FLX) and reboxetine (RBX)).
Moreover, to verify if the monoaminergic input, absent
in dissociated cultures, is necessary for the modulation
of BDNF and CRE promoters activity, we also studied
the effects of incubation of neuronal cultures with selec-
tive serotonergic or noradrenergic agonists.
We found that the incubation in vitro of neuronal
cultures with FLX and RBX was not able to increase the
transcription of BDNF promoters I, II, IV and CRE, likely
due to the lack of serotonergic and noradrenergic sub-
cortical afferents. However, the acute treatment of
cultures with distinct serotonergic and noradrenergic
agonists exerted a selective and distinct transcriptional
activation of BDNF promoters I, II, IV and CRE.
Methods
Plasmid construction
The BDNF promoter regions of exons 1, 2 and 4
(Timmusk et al., 1993) (from −528 bp upstream from
the initiation site to +138 bp downstream, for promoter
I; from −830 to +100 bp, for promoter II; from −629 to
+281 bp, for promoter IV) were ampliﬁed from rat geno-
mic DNA. Primers were designed in order that each pro-
moter has two different digestion sites (XhoI and HindIII
for promoters I and IV and BglII and MluI for promoter
II), for a directional insertion in the Fireﬂy luciferase
expression vector (pGL3-Basic Vector, Promega Italy SRL,
Italy) (Table 1). The ampliﬁed sequences were subcloned
in pGEM-T Easy Vector (Promega). Promoter sequences
were checked by sequencing, starting from both ends
(Value Read DNA sequencing service, MWG-Biotech,
Germany). Each promoter was excised from the cloning
vector, puriﬁed by electrophoresis and ligated into
pGL3-Basic Vector. The constructs obtained (pGL3-BDNF
promoter I, pGL3-BDNF promoter II, pGL3-BDNF pro-
moter IV) were sequenced, ampliﬁed and puriﬁed with
Endo-Free Plasmid Maxi Kit (Qiagen, Italy).
As an internal control, we used Renilla luciferase
vector (pRL Vector, Promega) carrying the rat elongation
factor 1α promoter (EF1α), which is non-responsive to
calcium signals and drug treatments (Tabuchi et al.,
1998) (EF1α-pRL). This construct was generated in the
same way as the experimental vectors (see Table 1 for pri-
mers used for cloning).
Primary neuronal cultures preparation
Primary cultures of rat hippocampal and cortical neurons
were prepared from 17–18 d old rat embryos by trypsin
+DNAse (Sigma-Aldrich Italy, Italy) treatment and mech-
anical dissociation in Hanks’ Balanced Salt Solution
(HBSS) (Invitrogen S.R.L., Italy). Cultures used for the
measurement of endogenous expression of BDNF exons
were not transfected; for other experiments, neurons
were transfected before plating (see below). All cultures
were grown in Neurobasal medium, containing B27
supplement, glutamine and penicillin/streptomycin
(Invitrogen) and incubated at 37 °C in a humidiﬁed CO2
(5%) incubator (Brewer et al., 1993). Experimental proce-
dures on animals were performed in accordance with
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the European Community Council Directive 86/609/EEC,
and were approved by Italian legislation on animal
experimentation (Decreto Legislativo 116/1992).
RNA isolation, cDNA synthesis and reverse
transcription-PCR for BDNF isoforms
Neurons were seeded in Poly-D-Lisine (Invitrogen)/
Laminin (Becton Dickinson Italy, Italy) coated six-well
plates at 5×105/well. Depolarization was performed
after 7 or 14 d in vitro (DIV) with 25mM KCl for 6 h
(Tabuchi et al., 2002). Total RNA was extracted using
Trizol reagent (Invitrogen) and reverse transcribed with
ImProm-II Reverse Transcription System (Promega)
(Donnici et al., 2008). cDNA was ampliﬁed with selective
primers (Table 2). BDNF exons were ampliﬁed together
with glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) mRNA, used as housekeeping (Table 2). The
number of cycles and primer concentrations were
chosen experimentally to stay within the exponential
phases of the ampliﬁcation reaction. For semi-quantitative
analysis, amplicons were detected by gel electrophoresis
(0.8% agarose, ethidium bromide staining). Bands were
acquired with Bio-Rad GelDoc System (Bio-Rad Lab-
oratories, Italy), intensities were measured with Quantity
One software (Bio-Rad Laboratories) and normalized on
GAPDH.
Immunocytochemistry
Rat neurons were electroporated (3×106 per transfection),
in Rat Neuron Nucleofector Solution, using Amaxa
Nucleofector program G-13 (Amaxa Gmb, Germany),
with 3mg of a plasmid carrying the coding sequence
of green ﬂuorescent protein under SV40 promoter
(pSV40-GFP) and plated at 1×105/well on coated 13mm
coverslips. After 7, 10 or 14 DIV, cells were ﬁxed with
4% paraformaldehyde. Primary antibodies used were
a monoclonal antibody against the neuron-speciﬁc
nuclear protein NeuN (Chemicon, USA) and polyclonal
antibodies against the glia-speciﬁc glial ﬁbrillary acid pro-
tein (GFAP) (Dako Italy SpA, Italy) and microtubule-
associated protein 2 (MAP-2) (Chemicon). Secondary
antibodies used were anti-mouse Rhodamine-conjugated
and/or anti-rabbit Cy5-conjugated antibodies. 40 ﬁelds
were analysed with AxioVision 4.3 microscope (Carl
Zeiss Vision GmbH, Germany); 40×magniﬁcation,
10 ﬁelds in four dishes.
Transfection of neurons with pGL3-BDNF promoter I,
pGL3-BDNF promoter II, pGL3-BDNF promoter IV and
pGL3-CRE
Rat neurons were electroporated (2–5×106 per trans-
fection) with 3mg of total DNA in a 5:1 molar ratio be-
tween the experimental vector (pGL3-BDNF promoter I,
pGL3-BDNF promoter II, pGL3-BDNF promoter IV or
pGL3-CRE) and the internal control EF1α-pRL, in Rat
Neuron Nucleofector Solution, using Amaxa Nucleo-
fector, program G-13 (Amaxa GmbH). Neurons were
then plated 7.5–10×104 on coated 96-well plates and
kept in culture for 7, 10 or 14 DIV (for details, see below).
In vitro drug treatment of neurons transfected with
pGL3-BDNF promoter I, pGL3-BDNF promoter II,
pGL3-BDNF promoter IV and pGL3-CRE
In vitro depolarization was performed after 7, 10 or 14
DIV with 25mM KCl for 6 h (Tabuchi et al., 2002).
Treatments with FLX (a selective 5-HT reuptake
inhibitor) and RBX (a selective NA reuptake inhibitor)
were performed by incubating cultures with 2, 5 or
Table 1. Sequences of primers used for the cloning of promoter regions from rat genomic DNA
Promoter Primer forward Primer review
BDNF I ACACTCGAGGGATCCTCCCCTCCTAGCC GAAAAGCTTCGCCTTGTCAGGCTAGGG
BDNF II CCAACGCGTATTACCTTCCAGCATCTGTTGG AATAGATCTAACTTCAGCGAGCTCAATGAGG
BDNF IV CCGCTCGAGCAAGAGGCTGTGACACTATGC CCGAAGCTTCAGTCACTACTTGTCAAAG
EF1α GGCAGATCTAGAGTAATTCATACAAAAGGAGGG GGCACGCGTGTTGCTTTGAATTAGCGGTGGCTTTC
Table 2. Sequences of primers used for RT-PCR
Primer forward Primer review
BDNF exon 1 ACTCAAAGGGAAACGTGTCTCT GCCTTCATGCAACCGAAGTA
BDNF exon 2 CGGTGTAGGCTGGAATAGACT GCCTTCATGCAACCGAAGTA
BDNF exon 4 CTCCGCCATGCAATTTCCACT GCCTTCATGCAACCGAAGTA
BDNF exon 6 GTGACAACAATGTGACTCCACT GCCTTCATGCAACCGAAGTA
GAPDH CAATGACCCCTTCATTGACC AGTTGTCATGGATGACCTTGG
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10 μM FLX or RBX hydrochloride for 6, 24, 48 or 72 h be-
fore luciferase expression measurement; treatment with
lithium was performed by incubating cultures with 1
mM lithium carbonate (Sigma-Aldrich) for 24 or 72 h
before luciferase expression measurement (all cultures
were maintained for 10 DIV).
Treatment with BDNF was performed in 10 DIV cul-
tures with 60 ng/ml in HBSS (Sigma-Aldrich) for 10min;
luciferase expression was measured after 6 h. Incubations
with selective receptor agonists and antagonists were per-
formed in 10 DIV cultures, treating neurons for 10min
in HBSS with 3 or 10 μM 5-HT, (R)-(+)-8-Hydroxy-DPAT
hydrobromide (8-OH-DPAT) (a full 5-HT1A serotonin
receptor agonist; active enantiomer), (R)(−)-DOI hydro-
chloride (DOI) (a potent and selective 5-HT2 serotonin
receptor agonist), NA, (−)-Isoproterenol hydrochloride
(a β-adrenoceptor agonist) or (R)-(−)-Phenylephrine
hydrochloride (a α1-adrenoceptor agonist). Luciferase
expression was measured after 60min.
All drug concentrations were chosen to expose neuro-
nal cultures to a drug concentration as close as possible
to those reached in brain tissue after (systemic) adminis-
tration in vivo. It was shown that the therapeutic con-
centrations of monoaminergic antidepressants in human
plasma are around 1 μM (Kelly et al., 1989; DeVane,
1999), but the concentrations in brain are higher (Karson
et al., 1993; Strauss et al., 1997). Clinically relevant extra-
cellular concentrations of lithium are in the low mM
range. Electrophysiological effects of 5-HT, NA and
monoaminergic agonists and antidepressants have been
studied in the micromolar concentration range (Mueller
et al., 1981; Krause and Jia, 2005).
Measurement of luciferase expression
For the measurement of both Fireﬂy and Renilla luciferases
levels, Dual-Glo® Luciferase Assay System (Promega)
was used, following manufacturer instructions. A plate
reader beta counter (Beckman Coulter, Italy) was used
for the detection of light emission.
Statistical analysis
To analyse the results of endogenous BDNF exons, two-
way analysis of variance (ANOVA) for the variables
days in culture and treatment (KCl), followed by
Bonferroni’s post-hoc multiple comparison test (BPHT)
was used. To analyse luciferase expression induced by
depolarization in neuronal cultures transfected with
pGL3-BDNFprI, pGL3-BDNFprII and pGL3-BDNFprIV,
two-tailed Student’s t-test for unpaired samples was
used. In time–course experiments of BDNF and CRE pro-
moters activity after in vitro incubation with anti-
depressants, two-way ANOVA for the variables time
and treatment, followed by BPHT, was performed. For
the study of the effects of in vitro treatment with BDNF,
serotonergic and noradrenergic agonists on transcription
activity of BDNF and CRE promoters, one-way ANOVA,
followed by BPHT, was applied.
In all tests used, signiﬁcance was assumed at
p<0.05. Statistical analyses were carried out using
GraphPadPrism4 (GraphPadSoftwareInc., USA).
Results
Endogenous expression of BDNF exons 1, 2, 4
(but not 6) is induced by depolarization
Because it is well established that total BDNF mRNA
transcription is activated by membrane depolarization
(Tabuchi et al., 2000; Tao et al., 2002; Pruunsild et al.,
2011), we ﬁrst investigated the effects of KCl stimulation
of hippocampal cultures on the endogenous expression of
the most abundantly expressed BDNF exons (transcripts
1, 2, 4 and 6) by RT-PCR. We found that, both in 7 and
14 DIV cultured hippocampal neurons, the expression
of exons 1, 2 and 4 containing transcripts was markedly
up-regulated by membrane depolarization (two-way
ANOVA, signiﬁcant effect of KCl; exon 1: F1,16 =88.04
p<0.001, BPTH: p<0.001 KCl vs. respective CNT; exon
2: F1,16 =16.53 p<0.001, BPTH p<0.01 KCl 7 DIV vs. re-
spective CNT, p<0.05 KCl 14 DIV vs. respective CNT;
exon 3: F1,16 =38.48 p<0.001, BPTH p<0.01 KCl vs. respect-
ive CNT) (Fig. 1a–c), whereas the expression of the exon
6 was not changed by in vitro stimulation (two-way
ANOVA; no effect of KCl: F1,16=0.07 p=0.79) (Fig. 1d).
Our results are in line with previous studies (Tabuchi
et al., 2002; Pruunsild et al., 2011).
Evaluation of transfection efﬁciency and of in vitro
neuronal maturation
Before transfecting neurons with BDNF promoter vectors,
we used immunocytochemistry to assess the transfection
efﬁciency and in vitro viability of rat neurons transfected
with the Amaxa Nucleofector system. Moreover, to
check for possible interference of glial cells, we also mea-
sured the percentage of astroglia and assessed whether
astroglia could be transfected. Rat hippocampal cultures
were transfected with a plasmid carrying the coding se-
quence of GFP under the constitutive promoter SV40
(see Material and Methods for details).
Interestingly, the percentage of GFP positive (trans-
fected) cells was similar in 7, 10 and 14 DIV (66.17±
3.47%, 63.44±3.063% and 65.03±3.29%, respectively,
one-way ANOVA, F2,58 =2.69, R
2=0.089, p=0.077) (Sup-
plementary Figure S1), suggesting high transfection
efﬁciency (as previously reported, Gärtner et al., 2006)
and good viability of transfected cells. However, GFAP
positive (glia) cells were 32.37±3.09% in 7 DIV culture,
39.36±2,87% in 10 DIV and 52.79±4.08% in 14 DIV, sug-
gesting in vitro growth of astroglia (one-way ANOVA,
F2,56=9.65, R
2=0.28, p<0.001, BPHT: p<0.001 14 DIV vs.
7 DIV, p<0.05 14 DIV vs. 10 DIV) (Supplementary
Figure S1). Interestingly, we also found that the number
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of NeuN positive (neurons) transfected cells was sig-
niﬁcantly reduced in 14 DIV compared with 7 DIV
(7 DIV 84.28±3.74%, 10 DIV 75.87±4.83%, 14 DIV
69.61±2.89%; one-way ANOVA, F2,59=3.36, R
2=0.10,
p<0.05; BPHT: p<0.05 14 DIV vs. 7 DIV) (Supplementary
Figure S1).
We also used immunocytochemistry to assess the level
of neuronal maturation, immunostaining cultures with
MAP-2, allowing visualization of dendritic arborization.
We found that all cultures were MAP-2 positive, but
7 DIV cultures showed low dendritic ramiﬁcation, com-
pared to 10 and 14 DIV (compare Supplementary
Figure S2b with Supplementary Figure S2e–h).
Together, these results showed that, on the one hand, in
7 DIV cultures, astroglia contamination is low and the
high majority of transfected cells were neurons, but den-
dritic arborization is poor. On the other hand, in 14 DIV
cultures, despite neurons reaching a good state of matu-
ration, the astroglia percentage signiﬁcantly increased,
and neurons percentage in the transfected population
decreased. Therefore, in all further experiments, we used
10 DIV cultures, which showed an adequate neuronal
maturation with lower interference of transfected glial
cells compared with 14 DIV cultures.
In vitro depolarization of neurons transfected with
pGL3-BDNF promoter I, II and IV constructs and
luciferase assay
In hippocampal cultures transfected with pGL3-BDNF
promoter I, we observed a 10-fold increase of the ex-
pression of luciferase after depolarization (Student’s
t-test, p<0.001) (Fig. 2a) while, after transfection with
pGL3-BDNF promoter II or IV vectors, KCl evoked a
two- to three-fold increase of luciferase transcription
(Student’s t-test, p<0.001) (Fig. 2b, c). Interestingly, in
hippocampal cultures, the induction of luciferase ex-
pression, resulting from depolarization-dependent acti-
vation of BDNF promoters I, II and IV, was in line with
the results obtained with endogenous transcription of
exons I, II and IV (compare Fig. 1 and Fig. 2a–c). Also
in cortical cultures we measured a signiﬁcant increase
of luciferase expression induced by in vitro depolariz-
ation, similar to the endogenous transcription of exons
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Fig. 1. Endogenous expression levels of BDNF exon I, II, IV and VI in 7 and 14 d in vitro (DIV) hippocampal cultures. Expression
level of BDNF exon I (a), II (b), IV (c), VI (d) in 7 and 14DIV hippocampal cultures in basal conditions (CNT, white bars) and after
6 h in vitro depolarization with KCl 25mM (black bars), measured with RT-PCR. Data are normalized on GAPDH levels and
expressed as fold change vs. CNT±S.E.M. Statistics: two-way ANOVA followed by BPHT. *p<0.05; **p<0.01; ***p<0.001 vs. CNT,
n=6, two independent experiments.
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1, 2 and 4 previously reported (Tabuchi et al., 2002). In
particular, we found that depolarization induced a more
than three-fold increase in the expression under BDNF
promoter I and about a two-fold increase of luciferase
in neurons transfected with pGL3-BDNF promoter II
or IV (Student’s t-test, p<0.001) (Fig. 2d–f).
Effect of in vitro treatment with ﬂuoxetine and
reboxetine on transcriptional activity of BDNF
promoter I, II and IV
We used the described gene reporter system to assess the
effect of treatment with clinically used antidepressants on
BDNF promoters activity. Since we have obtained similar
results with both hippocampal and cortical cultures
(see Fig. 2 above), we performed all subsequent experi-
ments on cortical neurons to limit the number of animals
used. Rat cortical neurons were alternatively transfected
with pGL3-BDNF promoter I, II or IV and cultures
were treated with 2, 5 and 10 μM FLX or RBX, for 6, 24
and 48 h. 25mM KCl for 6 h was used as a positive control
and luciferase expression was measured at 10 DIV.
As previously found, KCl depolarization activated
BDNF promoter activity (BDNF promoter I: CNT
100±4.60, KCl 392.4±10.98, n=6; BDNF promoter II:
CNT 100±3.88, KCl 177.00±6.08, n=6; BDNF promoter
IV: CNT 100±4.80, KCl 340.7±9.19, n=6). However, we
found no signiﬁcant increase of luciferase expression
after incubation with FLX and RBX at any concentration
and time point, with the single exception of BDNF pro-
moter IV after 6 h of RBX (two-way ANOVA; BDNF pro-
moter I FLX: no effect of time F3,36=0.57 p=0.67,
concentration F2,36=2.94 p=0.07, interaction F6,36=1.80
p=0.13; BDNF promoter I RBX: no effect of time F3,36 =
2.95 p=0.06, concentration F2,36 =0.71 p=0.50, interaction
F6,36=1.33 p=0.27; BDNF promoter II FLX: no effect of
time F3,36 =0.55 p=0.58, concentration F2,36=2.98 p=0.06,
interaction F6,36=1.36 p=0.26; BDNF promoter II RBX: no
effect of time F3,35=2.97 p=0.06, concentration F2,35=0.09
p=0.91, interaction F6,35=1.11 p=0.37; BDNF promoter
IV FLX: no effect of time F3,36=2.93 p=0.06, concentration
F2,36=0.75 p=0.46, interaction F6,36 =1.26 p=0.31;
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Fig. 2. Luciferase expression levels induced by in vitro depolarization of neuronal cultures transfected with pGL3-BDNFprI,
pGL3-BDNFprII and pGL3-BDNFprIV. Fireﬂy luciferase expression levels induced by 6 h depolarization with KCl 25mM of 10 d in
vitro hippocampal (a–c) or cortical (d–f) cultures alternatively transfected with pGL3-BDNFprI/EF1α-pRL (a, d), pGL3-BDNFprII/
EF1α-pRL (b,e) or pGL3-BDNFprIV/EF1α-pRL (c,f). Data are normalized on Renilla Luciferase expression levels and expressed as
fold change vs. CNT±S.E.M. Statistics: two-tailed Student’s t-test for unpaired samples. ***p<0.001 vs. CNT, n=6–10, two independent
experiments.
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BDNF promoter IV RBX: signiﬁcant effect of time
F3,33=18.49 p<0.001, concentration F2,33=14.75 p<0.001,
interaction F6,33=6.59 p<0.0001, BPHT p<0.001 10 μM 6 h
vs. t=0) (Fig. 3).
These results suggested that in vitro treatment of neuro-
nal cultures with FLX or RBX does not cause induction
of BDNF promoters I, II, IV.
Effects of ﬂuoxetine, reboxetine and lithium on CRE
promoter activity in neurons transfected with
pGL3-CRE
Since monoamine reuptake inhibitor antidepressants
increase CRE activity (for a review, see Tardito et al.,
2006), we analysed the in vitro effect of FLX and RBX on
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Fig. 3. Time–course of BDNF promoters activity after incubation in vitro of transfected cortical cultures with increasing
concentrations of ﬂuoxetine and reboxetine. Fireﬂy luciferase expression levels in cortical cultures transfected with pGL3-BDNFprI/
EF1α-pRL (a,b), pGL3-BDNFprII/EF1α-pRL (c,d) or pGL3-BDNFprIV/EF1α-pRL (e,f) and incubated for 6, 24 and 48 h with 2, 5 10 μM
ﬂuoxetine (a,c,e) or reboxetine (b,d,f). Data are normalized and expressed as in Fig. 2. Statistics: two-way ANOVA, followed by
BPHT; *p<0.001 vs. untreated cultures, n=5.
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the transcriptional activation of CRE (present in the
sequences of BDNF promoters I and IV (Tabuchi et al.,
2002; Tao et al., 2002)). We also tested lithium (a mood
stabilizer), a drug with a mechanism different from
monoamine reuptake inhibitors, which is known to
increase phosphorylation of CREB and CRE activity
(Einat et al., 2003). With these experiments we also
assessed if the effects on CRE activity of FLX, RBX and
lithium were modiﬁed by in vitro depolarization.
We transfected cortical neurons with pGL3-CRE
and treated neurons with 2 μM FLX or RBX for 6, 24, 48
and 72 h or with 1mM lithium carbonate for 24 and 72
h. At 10 DIV, cultures were depolarized (with 25mM
KCl, as above) and luciferase expression was measured.
As expected, depolarization caused a high induction
of CRE transcriptional activity with about a seven-fold
increase of luciferase expression in untreated cultures
(two-way ANOVA followed by BPHT; FLX: signiﬁcant
effect of KCl F1,49 =1073 p<0.001, time F4,49 =33.26
p<0.001, interaction F4,49 =30.37 p<0.001, BPHT p<0.001;
RBX: signiﬁcant effect of KCl F1,50=905.61 p<0.001, time
F4,50=7.39 p<0.001, interaction F4,50 =5.31 p=0.001, BPHT
p<0.001 vs. respective CNT) (Fig. 4a, b). Instead, both
FLX and RBX were not able to induce activation of CRE
and rather decreased its activation after depolarization
(BPHT p<0.001 vs. KCl t=0), suggesting a reduction of
neuronal responsiveness (Fig. 4a, b).
On the contrary, the incubation of neuronal cultures
with 1mM lithium (Fig. 4c) induced a marked and time-
dependent activation of CRE in basal conditions
(two-way ANOVA followed by BPHT; FLX: signiﬁcant ef-
fect of KCl F1,27=87.11 p<0.001, time F2,27 =46.95 p<0.001,
interaction F2,27 =124.32 p<0.001): we found a four-fold
increase of luciferase expression after 24 h and a further
increase, up to more than eight-fold, after 72 h (BPHT
p<0.001 24 h vs. t=0, 72 h vs. 24 h and t=0). In depolarized
cultures, after incubation with lithium for 24 h, we regis-
tered an increase of luciferase expression (signiﬁcantly
higher than the levels measured in both lithium-untreated
depolarized, BPHT p<0.001, and 24 h lithium-treated
non-depolarized neurons, BPHT p<0.001). Instead, in
cultures treated with lithium for 72 h, depolarization did
not induce an increase of CRE-mediated transcription
and, on the contrary, luciferase activity was signiﬁcantly
lower than that found in both lithium-untreated depo-
larized (BPHT p<0.001) and 72 h lithium-treated non-
depolarized neuron (BPHT p<0.001).
These results suggested that: (1) neuronal cultures do
not respond to FLX and RBX; (2) in neuronal cultures
CRE activity is increased by chronic lithium; (3) lithium
biphasically modulates CRE transcriptional activity de-
pending on the length of treatment and on neuronal
activation.
Effect of in vitro treatment with BDNF, serotonergic
and noradrenergic agonists on transcriptional activity
of BDNF promoter I, II and IV
Finally, we characterized the role of monoaminergic
input in the activation of selected BDNF promoters.
To this aim, we measured luciferase expression in cortical
neurons transfected with pGL3-BDNF promoter I, II and
IV or pGL3-CRE, after treatments of cultures with 5-HT,
8-OH-DPAT (5-HT1A agonist), DOI (5-HT2 agonist),
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Fig. 4. Time–course of CRE promoter activity after incubation
in vitro of transfected cortical cultures with ﬂuoxetine,
reboxetine and lithium carbonate, under depolarization
conditions. Fireﬂy luciferase expression levels in cortical
cultures transfected with pGL3-CRE/EF1α-pRL, incubated for
6, 24, 48 and 72 h with 2 μM ﬂuoxetine (a) or reboxetine (b) and
depolarized in vitro with 25mM KCl. (c) Fireﬂy luciferase
expression levels in cortical cultures transfected with
pGL3-CRE/EF1α-pRL, incubated for 24 and 72 h with 1mM
lithium carbonate and depolarized in vitro with 25mM KCl.
Data are normalized and expressed as in Fig. 2. Statistics:
two-way ANOVA followed by BPHT; ‡p<0.001 vs. basal
condition, untreated, for each experimental time (t=0, 6, 24, 48
or 72 h); *p<0.001 vs. depolarized untreated cultures (t=0);
§p<0.001 vs. basal untreated (t=0); #p<0.001 vs. basal untreated
t=24 h; $p<0.001 vs. depolarized treated t=24 h; n=6.
786 L. Musazzi et al.
NA, isoproterenol (β-adrenoceptor agonist) and phenyl-
ephrine (α1-adrenoceptor agonist). Moreover, since it is
well established that BDNF activates a positive feedback
mechanism (Acheson et al., 1995; Yoshii and
Constantine-Paton, 2010), we also evaluated the effect of
treatment with BDNF. Luciferase expression was assayed
after 6 h for BDNF and after 1 h for the other substances
(see Materials and Methods for details). 6 h of depolariza-
tion with 25mM KCl was used as a positive control.
Our results showed different responses, suggesting a
speciﬁc regulation of each BDNF promoter. BDNF pro-
moter I activity was signiﬁcantly increased by treatment
with BDNF and showed a general trend to increase
after both serotonergic and noradrenergic stimuli, that
reaches signiﬁcance only for serotonergic agents at the
lower concentration (one-way ANOVA, F14,250=18.53,
R2=0.52, p<0.001; BPHT: see Supplementary Table S1)
(Fig. 5a). BDNF promoter II-dependent transcription
was induced by both serotonergic and noradrenergic
stimuli, but not by BDNF (one-way ANOVA, F14,211 =
5.93, R2=0.30, p<0.001; BPHT: see Supplementary
Table S2) (Fig. 5b). We measured a selective induction
of BDNF promoter IV transcription after treatment with
BDNF and 5-HT1A agonists (5-HT and 8OH-DPAT),
but no effect of DOI and noradrenergic inputs (one-way
ANOVA, F14,194 =14.74, R
2=0.54, p<0.001; BPHT: see
Supplementary Table S3) (Fig. 5c). Finally, all compounds,
although to different degrees, markedly increased CRE
transcriptional activity (one-way ANOVA, F14,191=14.83,
R2=0.73, p<0.001; BPHT: see Supplementary Table S4)
(Fig. 5d).
Discussion
Generation of a gene-reporter system for the study
of BDNF promoters activity
In the present study we ﬁrst assessed basal and
depolarization-evoked endogenous transcription of the
four most highly expressed non-coding exons of the rat
BDNF gene (1, 2, 4, 6). In line with previous studies,
we found that the expression of exons 1, 2 and 4 was
markedly up-regulated by membrane depolarization,
while expression of the exon 6 was unchanged (Tabuchi
et al., 2002; Pruunsild et al., 2011). Then, we generated a
reporter gene assay based on transfection of rat primary
neuronal cultures with a high-efﬁciency transfection sys-
tem. At 10 DIV, we found around 60% of transfected
cells (Gresch et al., 2004; Leclere et al., 2005; Gärtner
et al., 2006), neurons showed good dendrite arborization
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Fig. 5. Effect of in vitro treatment with BDNF, serotonergic
and noradrenergic agonists on transcription activity of BDNF
promoter I, promoter II and promoter IV. Fireﬂy Luciferase
expression levels in cortical neurons transfected with
pGL3-BDNFprI/EF1α-pRL (a), pGL3-BDNFprII/EF1α-pRL
(b) or pGL3-BDNFprIV/EF1α-pRL (c) treated 10′ with BDNF
60 ng/ml or serotonin (5-HT), 8-hydroxy-DPAT hydrobromide
(8-OH-DPAT), (R)(−)-DOI hydrochloride (DOI), norepinephrine
(NE), isoproterenol (ISO) and phenylephrine (PHEN) 3 and
10 μM. Luciferase expression was assayed after 5 h for BDNF
and after 1 h for the other drugs. 6 h of depolarization with
25mM KCl was used as internal control. Data are normalized
and expressed as in Fig. 2. Statistics: one-way ANOVA, BPHT;
*p<0.05, **p<0.01, ***p<0.001 vs. untreated neurons, n=6–10,
two independent experiments.
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and the astroglial population showed low transfection
efficiency and moderate growth, suggesting that the
majority of transfected cells in culture were neurons and
ensuring lack of interference from astroglia. In neurons
transfected with BDNF promoters I, II and IV, we
found that in vitro depolarization caused a marked in-
duction of luciferase expression, similar to the observed
depolarization-evoked transcription of endogenous BDNF
exons. Thus, we generated a highly sensitive and rapidly
detectable gene reporter system, able to reproduce the
activation of endogenous BDNF promoters in response
to stimuli.
Characterization of the effects of treatments with
ﬂuoxetine and reboxetine on the transcriptional activity
of BDNF promoters and CRE. Bimodal action of
lithium on CRE-driven transcription
We then evaluated the direct effects of monoaminergic
antidepressants on BDNF promoters, measuring lucifer-
ase expression in neuronal cultures alternatively trans-
fected with BDNF promoter I, II and IV and incubated
with 2, 5 or 10 μM FLX or RBX for 6, 24 and 48 h. We
found that neither FLX nor RBX were able to induce
BDNF promoters transcriptional activities, at any time
point considered. Interestingly, the same results were
obtained in cultures transfected with pGL3-CRE. Since
transcriptional activation of CRE is a common target of
antidepressants (Carlezon et al., 2005; Malberg and
Blendy, 2005; Duman and Monteggia, 2006; Tardito
et al., 2006, 2009; Pittenger and Duman, 2008), the lack
of changes in luciferase expression under CRE promoter
after in vitro incubation with FLX and RBX suggested
that their effects are mediated by changes in the mono-
aminergic input. Indeed, cortical neurons are mainly
glutamatergic or GABAergic and, contrary to cerebral
cortex in vivo, primary cortical cultures completely lack a
serotonergic/noradrenergic input from subcortical areas.
Although this hypothesis may appear somewhat obvious
there is little or no direct evidence for this thus far.
We also showed lithium, a mood stabilizer with a
mechanism independent of extracellular monoamine
levels, induced a marked and time-dependent increase
of CRE-driven luciferase transcription in pGL3-CRE
transfected cultures. These data were consistent with pre-
vious evidence showing that lithium activates endo-
genous CRE transcriptional activity (Ozaki and Chuang,
1997). Intriguingly, it was shown that treatments of corti-
cal neurons with lithium or valproic acid increase both
the levels of BDNF exon IV-containing transcripts, and
the activity of BDNF promoter IV (Yasuda et al., 2009).
Moreover, our data showed that chronic lithium basally
increases CRE activity, suggesting the activation of neuro-
trophic mechanisms, but at the same time, reduces the
response to depolarization, suggesting a bimodal action
of the drug, as previously argued by others (Jope, 1999).
According to this hypothesis, lithium could stabilize
intracellular signalling (including CRE-related pathways)
in an optimal range, which may contribute to avoiding
mood swings.
Characterization of the pharmacological modulation
of BDNF and CRE promoters by serotonergic and
noradrenergic stimuli
We found that FLX and RBX did not induce BDNF
promoter I, II, IV and CRE transcriptional activity in
neuronal cultures, most likely due to the absence of
monoaminergic inputs. To understand if an increase
of extracellular monoamine concentration is necessary to
activate BDNF- and CRE-promoted transcription, we
incubated with 5-HT or NA cortical neurons alternatively
transfected with pGL3-BDNF promoter I, II, IV or
pGL3-CRE. Moreover, to analyse what receptor subtypes
mediate the effects of 5-HT and NA, we also applied a full
5-HT1A agonist (8OH-DPAT), a selective 5-HT2 agonist
(DOI), a β-adrenoceptor agonist (isoproterenol) and an
α1-adrenoceptor agonist (phenylephrine). The results
obtained suggest a selective and distinct modulation of
BDNF transcription mediated by each speciﬁc promoter
in response to different receptor ligands.
We demonstrated that BDNF exerts a positive
feedback on its transcription levels by selectively activat-
ing promoters I and IV. We also observed that BDNF
activates CRE-mediated transcription. Since CRE is a re-
sponsive element present in BDNF promoters I and IV
(Shieh et al., 1998; Tabuchi et al., 2002), we speculate
that BDNF-dependent activation of BDNF promoters
I and IV was partly dependent by the induction of a
CRE element.
5-HT induced a marked activation of both CRE and
BDNF promoters. However, while for CRE and BDNF
promoters I and II the induction of transcription caused
by 5-HT seems to be mediated by both 5-HT1A and
5-HT2 serotonin receptors, BDNF promoter IV-mediated
transcription was increased selectively by the activation
of 5-HT1A receptors.
We also observed a speciﬁc regulation of selected
BDNF promoters after noradrenergic inputs. Indeed,
while CRE and BDNF promoter II were markedly
activated by all noradrenergic stimuli, BDNF promoter
IV transcription was totally independent of noradrenergic
stimuli, while BDNF promoter I activation by noradrener-
gic agents did not reach statistical signiﬁcance. Therefore,
although the sequences of BDNF promoters I and IV
contain a CRE element and CRE activity was markedly
up-regulated by noradrenergic inputs, BDNF promoters
showed a differential pattern of activation. It is known
that in BDNF promoters I and IV there are additional
responsive elements other than CRE (Tabuchi et al.,
2002; Tao et al., 2002; Pruunsild et al., 2011), that could
selectively modulate and partly reduce or eliminate
the response of BDNF promoters I and IV to noradrener-
gic stimuli.
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In the present study we investigated only BDNF pro-
moters I, II and IV because they have brain-enriched
expression patterns and are activated by depolarization
(Aid et al., 2007). However, we cannot exclude that
other promoters could contribute to the regulation of
BDNF gene transcription induced by monoaminergic
agonists. Moreover, extracellular levels of 5-HT or NA
could affect not only total BDNF mRNA level, but
also the intracellular trafﬁcking of the transcripts
(Baj et al., 2012).
In summary, our results suggest that cortical neuronal
cultures, due to the lack of serotonergic and noradrener-
gic/monoeminergic afferents, are not a suitable system
to study the effects induced by antidepressants that act
primarily by increasing extracellular levels of mono-
amines, such as FLX and RBX. On the other hand, neuro-
nal cultures transfected with BDNF-promoter reporters
may constitute a simple and reliable system to character-
ize the effect of selective monoaminergic receptor agonists
on neurotrophin signalling.
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